Hoth Therapeutics receives FDA clearance to proceed with Phase 2a trial of HT-001 for EGFR inhibitor skin toxicities

Hoth Therapeutics, Inc.

FDA completed safety review and permitted IND for HT-001 to treat rash and skin disorders from EGFR inhibitor therapy.
Phase 2a trial (CLEER) is a randomized, placebo-controlled, parallel dose-ranging study.
European patent application filed for compositions and methods treating lung inflammation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.